The primary objective of this study is to compare the effect of CT327 to placebo against experimental induced superficial, deep and hyperalgesic pain. The secondary objectives are to elucidate the mechanisms of CT327 using experimental pain models.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
24
During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications. During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.
Department of Gastroenterology Aalborg Hospital
Aalborg, Denmark
An alteration in the peripheral sensitisation after treatment with CT327
Time frame: 2 treatment/testing periods each lasting 4 days and separated by at least 10 days
The change in pain determined with the visual analogue scale (VAS) and the change in areas assessed with von Frey filaments and standardized brush.
Time frame: 2 treatment/testing periods each lasting 4 days and separated by at least 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.